Skip Navigation LinksHome > December 2002 - Volume 25 - Issue 6 > Predictive Value of P53, BCL-2, and BAX in Advanced Head and...
American Journal of Clinical Oncology:

Predictive Value of P53, BCL-2, and BAX in Advanced Head and Neck Carcinoma.

Casado, Susana Ph.D.; Forteza, Jerónimo Ph.D.; Dominguez, Severina M.D.; Abad, M. Teresa M.D.; Perez, Isabel M.D.; Intxaurbe, Iratxe M.D.; del Campo, J. M. M.D.; Lopez, Rafael Ph.D.

Collapse Box


Because the apoptotic process appears to be involved in the response-to-treatment of chemotherapy and radiotherapy, we investigated the prognostic value of the expression of three apoptosis-associated genes (p53, Bax, and Bcl-2) in tumor biopsies from patients with locally advanced head and neck carcinoma. Using specific monoclonal antibodies, immunohistochemical staining for p53, Bax, and Bcl-2 was performed on tumor material from 43 patients before their scheduled adjuvant chemoradiotherapy. Results indicated that the response to treatment was 83.7% (36 of 43 patients). Bax staining was positive in 8 cases (19.5%), p53 in 19 (47.5%), and Bcl-2 in 4 patients (10.8%). There were no statistically significant correlations between any of the apoptosis genes assayed and the patients' response to treatment or to overall survival. In the univariate statistical analysis, response-to-treatment was the only significant variable (p = 0.013) predictive of survival rate. These results suggest that p53, Bax, and Bcl-2 expression are not significant predictive factors of response to induction treatment in locally advanced head and neck carcinoma and that their routine use as prognostic markers cannot be recommended.

© 2002 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us


For additional oncology content, visit LWW Oncology Journals on Facebook.